Cardiology Research and Practice

Cancer and Cardiovascular Disease


Publishing date
15 Apr 2011
Status
Published
Submission deadline
15 Oct 2010

1Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

2Cardiology Unit, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy

3Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN 37232-8802, USA


Cancer and Cardiovascular Disease

Description

Cardiovascular disease and cancer are the two most common diseases worldwide. Despite advancement in prevention and treatment, they remain the leading causes of mortality with increasing burden to the patients, care givers, and the health care system. Extensive literature is available for the diagnosis and treatment of heart disease and cancer. Surprisingly, little data exist on the management of patients, who carry the diagnosis of both, cancer and cardiovascular disease. Guidelines for the treatment of cardiovascular disease are often based on studies which have excluded patients with cancer, and similarly studies in cancer population have generally excluded patients with concomitant heart disease. Cancer and cardiovascular disease are frequently found in the same patient, because of the high prevalence of both diseases, and because some forms of cardiovascular disease are caused by cancer or its therapies. Anthracyclines are known to cause cardiotoxicity and the newer therapeutic agents such as trastuzumab and tyrosine kinase inhibitors have collateral effects on the cardiovascular system. These include hypertension, ischemia, systolic and diastolic dysfunction. Radiation induced cardiac damage frequently affects the long-term survivors of cancer. Prevention and management of cardiotoxicity due to radiation and these chemotherapeutic agents are largely unknown.

The main focus of the issue will be to review existing evidence and provide latest research for the diagnosis, treatment, and prevention of cardiovascular disease in cancer patients. The special issue will become an international forum for researchers to summarize the most recent development and ideas in this field, with a special emphasis given to the latest basic and clinical research within the last 5 years.

Potential topics include, but are not limited to:

  • Basic mechanism of chemotherapy induced cardiomyopathy
  • Tyrosine kinase inhibitors and mechanisms of hypertension and left ventricular dysfunction
  • New research on the treatment of chemotherapy induced cardiomyopathy
  • Basic mechanism of radiation induced heart disease
  • Clinical aspects of radiation induced heart disease
  • Biomarkers in heart disease and cancer
  • Cardiac imaging in the cancer patients
  • Newer diagnostic modalities for the detection of cardiotoxicity
  • Thrombosis and cancer

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/crp/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:

Cardiology Research and Practice
 Journal metrics
See full report
Acceptance rate6%
Submission to final decision171 days
Acceptance to publication19 days
CiteScore3.600
Journal Citation Indicator0.400
Impact Factor2.1
 Submit Check your manuscript for errors before submitting

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.